Relying on a minority shareholding, the team supports the development of the company and its products for 2 to 6 years, and then sells its shares, most of the time to a large company which commercializes the products after the development is completed.
With close to € 450 million under management dedicated to the Life Sciences sector, Edmond de Rothschild Investment Partners leads the financing rounds of companies based mainly in Europe, and active in one of the following three areas: therapeutic products, medical devices and molecular diagnostics.
More specifically the activity of Life Sciences team at Edmond de Rothschild Investment Partners is distinguished by the following characteristics:
- Lead investor with a significant shareholding (15-25%)
- Strong involvement of the team, systematically hold Board positions in portfolio companies
- Support in the development of products from pre-clinical proof of concept, or prototype (medical devices), to the proof of concept in humans, or commercialisation (medical devices).